SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Korro entered into an exchange agreement with Venrock Healthcare Capital Partners on August 5, 2026, whereby Venrock surrendered 1,000,000 shares for no consideration and received pre-funded warrants to purchase 1,000,000 shares at $0.001 exercise price with no expiration date. The pre-funded warrants are immediately exercisable and represent a material dilutive issuance of equity securities that increases the company's outstanding share count.
View raw filing on EDGAR →Korro issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing cash position of $137.9 million, R&D expenses of $13.6 million, G&A expenses of $6.5 million, and a net loss of $18.9 million.
View raw filing on EDGAR →This is a clear earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 of Form 8-K. The press release reports revenues of $284 thousand, R&D expenses of $71.6 million, SG&A expenses of $55.0 million, and a net loss of $127.1 million, along with cash position of $981.5 million. The disclosure is material as it provides investors with the company's financial performance and cash runway information.
View raw filing on EDGAR →Vital Farms entered into two new senior secured credit facilities on August 4, 2026: a $125 million 3-year term loan facility and a $60 million 3-year asset-based revolving credit facility, replacing the prior $60 million revolving facility. The company borrowed the full $125 million term loan on the closing date, creating material new direct financial obligations totaling $185 million in aggregate credit capacity.
View raw filing on EDGAR →Vital Farms disclosed Q2 2026 financial results showing significant deterioration: net revenue of $166.0 million (down 10.1% year-over-year), gross margin collapsed from 38.9% to 6.6%, net loss of $31.1 million versus prior-year net income of $16.6 million, and adjusted EBITDA loss of $26.6 million, driven by industry-wide oversupply and pricing pressure. The company also revised full-year guidance and cancelled its stock repurchase program effective upon closing of the new credit facilities.
View raw filing on EDGAR →Joanne M. Maguire retired as a director effective immediately, reducing the Board size from eight to seven members. Thomas J. Manning was appointed to a committee in connection with this change.
View raw filing on EDGAR →The Company announced a special cash distribution of $5.00 per share payable on August 27, 2026, to stockholders of record as of August 17, 2026, funded by proceeds from the sale of the Ruckus Networks business. This distribution represents a material return of capital to shareholders.
View raw filing on EDGAR →This is a clear earnings release disclosing Cullinan Therapeutics' financial results for Q2 2026 and the six months ended June 30, 2026. The filing explicitly states "announced its financial results for the three and six months ended June 30, 2026" with a press release furnished as Exhibit 99.1. The exhibit contains consolidated statements of operations showing net loss of $53.7 million for Q2 2026 and $103.4 million for the six-month period, along with balance sheet data and detailed operating expense breakdowns. This is a material disclosure affecting investor assessment of the company's financial condition and operational performance.
View raw filing on EDGAR →Commerce.com issued a press release on August 6, 2026 announcing financial results for the second quarter and six months ended June 30, 2026. The disclosure includes key financial metrics (total revenue of $84.5 million, GAAP net income of $1.1 million, ARR of $360.5 million), operational highlights, and forward guidance for Q3 and full-year 2026. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is the designated Item for results of operations and financial condition.
View raw filing on EDGAR →Vistance Networks issued a press release on August 6, 2026 disclosing its financial results for the second quarter of 2026, including net sales of $319.6 million, GAAP income from continuing operations of $26.1 million, and non-GAAP adjusted EBITDA of $35.8 million. The press release is attached as Exhibit 99.1 and the company will host an earnings call to discuss these results, which is the standard format for quarterly earnings disclosures under Item 2.02.
View raw filing on EDGAR →Scholar Rock issued a press release on August 6, 2026 announcing its financial and operating results for the quarter ended June 30, 2026, including net loss of $109.9 million, R&D and G&A expenses, cash position of $492.1 million, and weighted average shares outstanding. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.
View raw filing on EDGAR →REGENXBIO issued a press release on August 6, 2026 disclosing its financial results and operational highlights for the quarter ended June 30, 2026. The disclosure includes detailed financial statements (balance sheet, revenues, R&D and G&A expenses, net income), cash position analysis, and forward-looking guidance on cash runway into Q4 2027. This is a standard quarterly earnings release furnished under Item 2.02, with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →FrontView REIT issued a press release on August 6, 2026 announcing second quarter 2026 financial results, including net income of $1.5 million ($0.03 per share), FFO of $7.2 million ($0.26 per share), and AFFO of $9.4 million ($0.33 per share), along with raised 2026 guidance for AFFO per share of $1.32–$1.34 and net investment guidance of $120.0 million.
View raw filing on EDGAR →This is a clear earnings release disclosing Nuvation Bio's Q2 2026 financial results, including $31.7 million in total revenue ($23.2 million in net product revenue for IBTROZI), R&D expenses of $30.7 million, SG&A expenses of $42.6 million, and a net loss of $62.8 million. The press release was issued on August 6, 2026, and is furnished as Exhibit 99.1 to the 8-K under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.
View raw filing on EDGAR →Climb Bio issued a press release on August 6, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed consolidated balance sheets and statements of operations. The disclosure includes cash position ($239.2 million), R&D expenses ($9.7 million), G&A expenses ($5.6 million), net loss ($13.5 million), and net loss per share ($0.18), along with business updates on clinical pipeline progress. This is a standard quarterly earnings release with financial statements attached as Exhibit 99.1, typical of Item 2.02 disclosures.
View raw filing on EDGAR →PepGen disclosed Q2 2026 financial results via press release, reporting a net loss of $17.8 million (improved from $23.1 million in Q2 2025), R&D expenses of $12.5 million, and a cash position of $117.2 million, along with condensed consolidated financial statements and per-share metrics.
View raw filing on EDGAR →PepGen announced that an independent Data and Safety Monitoring Board recommended advancing its Phase 2 FREEDOM2-DM1 study into the highest dose cohort (12.5 mg/kg) and dose escalation in the open-label extension study from 5 mg/kg to 10 mg/kg, representing a material clinical development milestone for the lead candidate PGN-EDODM1.
View raw filing on EDGAR →Lantheus announced via press release its financial results for the three and six months ended June 30, 2026, disclosing worldwide revenue of $388.2 million, GAAP fully diluted EPS of $1.11, and adjusted fully diluted EPS of $1.55. The Item 2.02 disclosure and attached Exhibit 99.1 press release are the classic format for earnings announcements. While the filing also mentions the pending Curium merger, the primary Item 2.02 content is the quarterly financial results disclosure.
View raw filing on EDGAR →This is a quarterly earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The disclosure includes consolidated statements of operations showing net loss of $106.6 million for Q2 2026, balance sheet data, and business updates on clinical programs (lonvo-z Phase 3 positive results, nex-z enrollment progress). The press release is furnished as Exhibit 99.1 and contains standard financial metrics and operational highlights typical of an earnings announcement.
View raw filing on EDGAR →Cars.com Inc. issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing revenue of $179.9 million (up 1% YoY), net income of $14.3 million (up 103% YoY), and Adjusted EBITDA of $53.0 million (up 4% YoY). The filing explicitly states this is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial highlights, operational metrics, cash flow data, and forward guidance for Q3 and full-year 2026.
View raw filing on EDGAR →Agenus announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure reports Q2 2026 revenue of $34.5 million (up from $25.7 million year-over-year), including $6.4 million in pre-commercial product revenue and $28.1 million in non-cash royalty revenue. This is a standard quarterly earnings release under Item 2.02, disclosing results of operations and financial condition.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release announces second quarter 2026 financial results, including net income of $2.6 million ($0.10/share), revenues of $17.4 million, and Adjusted EBITDA of $8.4 million, with detailed segment performance and forward guidance. The filing includes consolidated balance sheets and statements of operations, which are typical of quarterly earnings disclosures.
View raw filing on EDGAR →Radian Group Inc. issued a news release on August 5, 2026, announcing its financial results for the quarter ended June 30, 2026, disclosing net income from continuing operations of $118 million ($0.87 per diluted share) and adjusted diluted net operating income per share of $1.14. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings releases.
View raw filing on EDGAR →MBX Biosciences announced Q2 2026 financial results via press release, reporting R&D expenses of $31.0M (vs. $17.7M YoY), G&A expenses of $9.9M (vs. $4.1M YoY), net loss of $37.1M (vs. $19.4M YoY), and cash position of $418.6M expected to fund operations into 2029.
View raw filing on EDGAR →MBX Biosciences provided a clinical trial progress update for MBX 4291, a Phase 1 obesity candidate, confirming the company remains on track to report 12-week MAD (multiple ascending dose) data in Q4 2026.
View raw filing on EDGAR →ALX Oncology issued a press release on August 6, 2026, announcing its financial results for the second quarter ended June 30, 2026, including consolidated statements of operations, balance sheet data, and per-share metrics. The disclosure includes GAAP net loss of ($17.971) million and non-GAAP net loss of ($14.310) million for Q2 2026, along with cash position of $153.4 million and detailed operating expense breakdowns. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.
View raw filing on EDGAR →The filing discloses a press release issued on August 6, 2026, announcing preliminary financial information including cash on hand ($10.1 million as of August 3, 2026) and forward-looking revenue guidance (500%+ growth anticipated for fiscal year 2027). While the disclosure also includes listing compliance status and recent financing/milestone payment events, the Item 2.02 classification and the press release format are consistent with an earnings or financial results announcement. The preliminary nature and forward-looking guidance distinguish this from a full quarterly/annual earnings release, but it functions as a material financial update to investors.
View raw filing on EDGAR →BlackRock TCP Capital Corp. entered into and completed a material disposition on August 4, 2026, selling 95% of the equity interests in a continuation vehicle holding approximately $523 million of investments (representing ~48% of the company's debt portfolio fair value) to Pantheon-sponsored funds for approximately $152 million in gross proceeds, while retaining a 5% interest. The transaction materially reduced net leverage from 1.38x to approximately 0.4x pro forma and resulted in an estimated NAV decline of $0.68 per share.
View raw filing on EDGAR →BlackRock TCP Capital Corp. disclosed second quarter 2026 financial results, including net investment income of $18.1 million ($0.22 per share) and net asset value per share of $6.58, along with portfolio composition details.
View raw filing on EDGAR →ASP Isotopes announced that Renergen's subsidiary Tetra4 has entered into a five-year take-or-pay LNG supply contract with a South African food processor at greater than $16/GJ, representing approximately 10% of Phase 1 nameplate capacity and bringing total Phase 1 contracting to approximately 75%. This is a material operational and commercial milestone for the Virginia Gas Project's Phase 1 commercialization, expected to commence in Q3 2026, but does not fit the specific categories of M&A activity, debt issuance, or other defined financial events—it is a material commercial contract milestone supporting the company's operational strategy.
View raw filing on EDGAR →Corbus Pharmaceuticals reported Q2 2026 financial results for the quarter ended June 30, 2026, including a net loss of $35.0 million (compared to $17.7 million in Q2 2025), operating expenses of $36.2 million, and a cash position of $117.9 million. The press release furnished as Exhibit 99.1 presents condensed consolidated financial statements and operating metrics for the three and six months ended June 30, 2026.
View raw filing on EDGAR →Annexon disclosed positive interim clinical trial results from the FORWARD study showing rapid, clinically meaningful improvements in all ten tanruprubart-treated GBS patients within days, with data expected to support a BLA submission targeted for Q4 2026. While this is a clinical milestone for a biopharmaceutical company's lead investigational therapy, it does not fit neatly into earnings_release (no financial results disclosed), material_litigation, or other specific event types. The disclosure centers on a material operational/clinical development milestone that would affect investor assessment of the company's regulatory pathway and commercial prospects, making operational_other the most appropriate classification.
View raw filing on EDGAR →Oncor Electric Delivery Co LLC reported financial results for the three and six months ended June 30, 2026, with net income of $428 million for Q2 2026 (compared to $259 million in Q2 2025) and $640 million for the six-month period (compared to $440 million in the prior year). The earnings release, furnished as a press release and slide presentation with condensed consolidated financial statements, was disclosed via Items 2.02 and 7.01.
View raw filing on EDGAR →CG Oncology issued a press release on August 6, 2026 announcing second quarter 2026 financial results, including net loss of $79.1 million, R&D expenses of $54.7 million, and cash position of $1.0 billion.
View raw filing on EDGAR →CG Oncology filed Amendment No. 2 to its prospectus on August 6, 2026, increasing the shares available for sale under an Open Market Sale Agreement (ATM offering) with Jefferies LLC by an additional $500 million, following prior $550 million in sales.
View raw filing on EDGAR →Arteris, Inc. appointed Saurabh Sinha as Chief Financial Officer, effective September 8, 2026, succeeding retiring CFO Nick Hawkins. The appointment includes compensatory arrangements comprising a base salary of $440,000, target bonus of 60%, and equity awards totaling approximately $5.7 million in PSUs and RSUs.
View raw filing on EDGAR →Loar Holdings disclosed its Q2 2026 financial results on August 6, 2026, including net sales of $171.6 million (up 39.4% YoY), net income of $16.7 million, and adjusted EBITDA of $69.4 million (up 47.4% YoY), along with an upward revision to full-year 2026 guidance. The press release is furnished as Exhibit 99.1 and constitutes a standard earnings announcement under Item 2.02, which is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →This Item 2.02 discloses Montauk Renewables' unaudited consolidated financial results for the six months ended June 30, 2026, including revenue of $100.4 million (up 14% YoY), EBITDA of $21.1 million (up 85% YoY), and headline earnings per share of $0.01 (versus a loss of $0.03 in the prior year). The filing explicitly states the HEPS report was filed to comply with JSE reporting requirements and includes a salient features table with key financial metrics. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →Fold announced a strategic banking partnership with Lead Bank to serve as its core banking partner, supporting accounts, deposits, withdrawals, and bitcoin trading. This is a material operational and strategic event—a significant partnership that enhances Fold's financial infrastructure and enables expanded product capabilities—but does not fit the specific categories of M&A activity, debt issuance, or other named financial events. The partnership is foundational to Fold's ability to scale its consumer platform and launch new customer-facing features, making it material to investors assessing the company's operational trajectory.
View raw filing on EDGAR →Mastech Digital disclosed Q2 2026 financial results via press release, reporting revenues of $41.4 million (down 15.6% year-over-year), a GAAP net loss of $100K, and non-GAAP net income of $976K, along with detailed segment performance metrics and management commentary.
View raw filing on EDGAR →The company awarded 50,000 restricted stock units to CEO and President Nirav Patel with a three-year vesting schedule beginning August 1, 2026, representing a material equity incentive arrangement.
View raw filing on EDGAR →The Board of Directors declared quarterly cash dividends on common stock ($0.755 per share), Series A preferred stock ($0.390625 per share), and Series B preferred stock ($0.367200 per share), with specified record dates and payment dates. This is a routine but material dividend declaration by a REIT, affecting shareholder returns and capital allocation.
View raw filing on EDGAR →This is a standard earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026). The press release includes condensed consolidated balance sheets and statements of operations showing cash position of $190.0 million, R&D expenses of $12.9 million, and net loss of $16.6 million for the quarter. The disclosure is material as it provides investors with the company's financial performance and cash runway guidance into 2H 2028.
View raw filing on EDGAR →Warren Foust was appointed President, Chief Executive Officer, and Board member effective August 4, 2026, following an extensive global search. Deborah Andrews transitioned from Interim Co-CEO to Executive Vice President and Chief Financial Officer. The appointment includes substantial compensation arrangements including a base salary of $730,000 and significant equity grants.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of an annual shareholder meeting held on August 3, 2026. The filing presents voting results for four proposals: re-election of two Class II trustees (Matthew Bass and John G. Jordan), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of a new investment advisory agreement with AB Private Credit Investors LLC. All proposals passed unanimously with 4,716,152 votes in favor and zero votes against or withheld, constituting a quorum of the 6,604,286 outstanding shares.
View raw filing on EDGAR →The 6-K discloses material clinical trial updates for Ascendis's achondroplasia programs, including Week 78 COACH combination therapy results showing sustained efficacy at the 97th percentile growth velocity, Week 104 ApproaCH monotherapy data, and YUVIWEL U.S. launch progress (170+ patient enrollments, 65%+ reimbursement approval). These are significant operational and clinical development milestones that would affect investor assessment of the company's pipeline and commercialization trajectory, though they do not fit neatly into discrete event categories like earnings_release or ma_activity.
View raw filing on EDGAR →The filing discloses unregistered sales of equity securities totaling approximately $25.1 million across multiple tranches (June 1, July 1, and August 3, 2026) to accredited investors under Section 4(a)(2) and Regulation D exemptions. These private placements of common shares of beneficial interest represent dilutive equity issuances material to the fund's capital structure and investor base.
View raw filing on EDGAR →This exhibit discloses the results of HDFC Bank's 32nd Annual General Meeting held on August 5, 2026, including voting outcomes on nine resolutions (both ordinary and special business). The document presents detailed voting tallies, shareholder participation, and the Scrutinizer's report confirming all resolutions passed with requisite majorities. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, material because it confirms shareholder approval of key matters including financial statements, dividend declaration, director appointments, and debt issuance authority.
View raw filing on EDGAR →The filing discloses an unregistered sale of 767,565 common shares for approximately $15.98 million under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive equity issuance in a continuous private offering, material to investors as it increases share count and dilutes existing shareholders' ownership interests.
View raw filing on EDGAR →Gogo Inc. issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing total revenue of $222.8 million, service revenue of $191.3 million, net loss of $2.0 million, and Adjusted EBITDA of $53.7 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.
View raw filing on EDGAR →